Redwood Pharma to provide digital presentations in connection with the rights issue

Redwood Pharma AB (publ) (“Redwood Pharma” or “the Company”) has arranged information presentations in connection with the Company’s rights issue with a subscription period 25 January – 8 February 2021. 

• Aktiespararna, Aktiedagen Lund 2020, 27 January, 13:15 – 13:45. The presentation will be webcast and streamed at The next day, the presentation will be posted on

• Erik Penser Bank, Company Presentation, 1 February. The presentation will be webcast and streamed at

Redwood Pharma’s CEO Martin Vidaeus will give digital company presentations and inform about the company’s development and future plans as well as an ongoing rights issue and move to Nasdaq First North stock exchange.

For more information:

Martin Vidaeus, CEO Redwood Pharma AB (publ)
Tel: +46 (0) 70 232 29 29

About Redwood Pharma

Redwood Pharma develops ophthalmic products for unmet medical needs through novel approaches. In providing commercial partners and their customers with effective medical solutions, the Company is currently developing treatments for dry eye disease in various target patient populations. The RP101 program targets moderate-to-severe dry eye disease in postmenopausal women by delivering a low-dose estrogen therapy to the front of the eye. The RP501 program aims to treat milder forms of dry eye in a broader patient population including both men and women of all ages. For other potential drug substances and therapeutic areas, the Company can employ the IntelliGel drug delivery platform that enhances patient convenience by controlling dosing and potentially reducing the number of instillations per day and subsequent side-effects. Redwood Pharma leverages its strengths in early clinical development and aims to generate revenues through, among others, licensing agreements with companies that have capabilities to manufacture and sell medical products worldwide.

Redwood Pharma AB (publ) is listed on the Spotlight Stock Market (Ticker: REDW.ST, ISIN: SE008294789).